These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 30959519)
1. Selection of Oral Antifungals for Initial Maintenance Therapy in Chronic Pulmonary Aspergillosis: A Longitudinal Analysis. Tashiro M; Takazono T; Saijo T; Yamamoto K; Imamura Y; Miyazaki T; Kakeya H; Ando T; Ogawa K; Kishi K; Tokimatsu I; Hayashi Y; Fujiuchi S; Yanagihara K; Miyazaki Y; Ichihara K; Mukae H; Kohno S; Izumikawa K Clin Infect Dis; 2020 Feb; 70(5):835-842. PubMed ID: 30959519 [TBL] [Abstract][Full Text] [Related]
2. High detection rate of azole-resistant Aspergillus fumigatus after treatment with azole antifungal drugs among patients with chronic pulmonary aspergillosis in a single hospital setting with low azole resistance. Takeda K; Suzuki J; Watanabe A; Arai T; Koiwa T; Shinfuku K; Narumoto O; Kawashima M; Fukami T; Tamura A; Nagai H; Matsui H; Kamei K Med Mycol; 2021 Apr; 59(4):327-334. PubMed ID: 32642756 [TBL] [Abstract][Full Text] [Related]
3. [An open, noncomparative multicenter study of the efficacy and safety of itraconazole injections and high dose capsules in chronic pulmonary aspergillosis]. Tomioka H; Kaneda T; Kida Y; Kaneko M; Fujii H; Hayashi M; Tomii K; Tada K; Suzuki Y; Karino T Kansenshogaku Zasshi; 2011 Nov; 85(6):644-51. PubMed ID: 22250455 [TBL] [Abstract][Full Text] [Related]
9. Serum Cytokine Changes in a Patient with Chronic Pulmonary Aspergillosis Overlapping with Allergic Bronchopulmonary Aspergillosis. Tsukamoto Y; Ito Y; Obase Y; Takazono T; Nakada N; Ashizawa N; Hirayama T; Takeda K; Ide S; Iwanaga N; Tashiro M; Hosogaya N; Fukahori S; Fukushima C; Yanagihara K; Izumikawa K; Mukae H Intern Med; 2024 Jun; 63(11):1659-1664. PubMed ID: 37899245 [TBL] [Abstract][Full Text] [Related]
10. Anti-fungal agents in the treatment of chronic pulmonary aspergillosis: Systematic review and a network meta-analysis. Sehgal IS; Dhooria S; Prasad KT; Muthu V; Aggarwal AN; Chakrabarti A; Agarwal R Mycoses; 2021 Sep; 64(9):1053-1061. PubMed ID: 34031920 [TBL] [Abstract][Full Text] [Related]
11. Effective plasma concentrations of itraconazole and its active metabolite for the treatment of pulmonary aspergillosis. Nakamura Y; Matsumoto K; Sato A; Morita K J Infect Chemother; 2020 Feb; 26(2):170-174. PubMed ID: 31481305 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of short- and long-term treatment of itraconazole on chronic necrotizing pulmonary aspergillosis in multicenter study. Yoshida K; Kurashima A; Kamei K; Oritsu M; Ando T; Yamamoto T; Niki Y J Infect Chemother; 2012 Jun; 18(3):378-85. PubMed ID: 22526387 [TBL] [Abstract][Full Text] [Related]
13. Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events. Bongomin F; Maguire N; Moore CB; Felton T; Rautemaa-Richardson R Mycoses; 2019 Mar; 62(3):217-222. PubMed ID: 30570179 [TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of sequential therapy with voriconazole on COPD patients in acute phase with pulmonary aspergillosis and effects on cytokines and pulmonary functions. Du JF; Chi YM; Song Z; Di QG; Shi J; Lv J; Mai ZT; Li M; Sun BH; Jiang MM Eur Rev Med Pharmacol Sci; 2018 Mar; 22(6):1837-1842. PubMed ID: 29630134 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan. Saito T; Fujiuchi S; Tao Y; Sasaki Y; Ogawa K; Suzuki K; Tada A; Kuba M; Kato T; Kawabata M; Kurashima A; Sakatani M; Infection; 2012 Dec; 40(6):661-7. PubMed ID: 22956473 [TBL] [Abstract][Full Text] [Related]
16. Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series. Cucchetto G; Cazzadori A; Conti M; Cascio GL; Braggio P; Concia E Infection; 2015 Jun; 43(3):277-86. PubMed ID: 25432571 [TBL] [Abstract][Full Text] [Related]
17. Tolerability of oral itraconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A systematic review and meta-analysis. Olum R; Baluku JB; Kazibwe A; Russell L; Bongomin F PLoS One; 2020; 15(10):e0240374. PubMed ID: 33052954 [TBL] [Abstract][Full Text] [Related]
18. An overview of the available treatments for chronic cavitary pulmonary aspergillosis. Sehgal IS; Dhooria S; Muthu V; Prasad KT; Agarwal R Expert Rev Respir Med; 2020 Jul; 14(7):715-727. PubMed ID: 32249630 [TBL] [Abstract][Full Text] [Related]
19. [Antifungal susceptibility of Candida species isolated from patient with invasive fungal peritonitis and investigation on clinical breakpoints of itraconazole]. Yamagishi Y; Terada M; Ohki E; Mikamo H Jpn J Antibiot; 2009 Oct; 62(5):415-34. PubMed ID: 20055119 [TBL] [Abstract][Full Text] [Related]
20. High-throughput simultaneousquantification offive azole anti-fungal agents and one active metabolite in human plasma using ultra-high-performance liquid chromatography coupled to tandem mass spectrometry. Tanaka R; Shiraiwa K; Takano K; Ogata M; Honda S; Yoshida N; Okuhiro K; Yoshida M; Narahara K; Kai M; Tatsuta R; Itoh H Clin Biochem; 2022 Jan; 99():87-96. PubMed ID: 34715112 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]